Resveratrol derivatives: a patent review (2009 – 2012)

Abstract

The ability of resveratrol to interact with a disparate array of subcellular targets is uncanny. Nonetheless, even though limited or no toxicity is apparent, the molecule is not a panacea due to lack of potency and issues with bioavailability. Thus, as witnessed by a number of patents, a large assortment of derivatives have been synthesized under the guise of having superior characteristics for treating or preventing various diseases or for use as neutraceutics and cosmetics. Some of these suppositions are probably correct, but evidence-based applications are essentially nil due to a lack of commitment in terms of investing the resources necessary for the conduct of obligatory clinical trials. Current usage is largely based on anecdotes and publicity. Hopefully, at some point in time, it will be possible to follow a standard protocol with a predicable outcome.

Resveratrol and Alzheimer’s disease: message in a bottle on red wine and cognition

“…In agreement, pterostilbene, a resveratrol derivative, has shown promise in preclinical models of neurodegeneration, resulting more efficient than resveratrol itself in modifying AD- and aging-related cognitive decline (Joseph et al, 2008; Chang et al, 2012). These results leave the door open for the use of newly synthesized resveratrol analogs in aging-related disorders (Bourzac, 2012; Ogas et al, 2013; Pezzuto et al, 2013). …”

Resveratrol and cancer: Challenges for clinical translation

“…In the recent past, a number of laboratories have attempted to synthesize novel resveratrol derivatives or formulations [33]. However, limited efforts have been put forward to determine if these derivatives are superior to resveratrol in relevant disease models.…”

Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases

“…A problem of patenting natural products was previously exemplified with curcumin [273, 274], whereas patenting guidelines also change for newly-discovered natural products [2]. Improving bioavailability of curcumin [275, 276], or generating derivatives of resveratrol [277, 278] are viable patenting strategies to improve their efficacy. To this end, combining natural products with disease-specific behavioral interventions via mHealth offers an additional level of intellectual property protection by merging copyrights (lasting over 50 years) with a pharmacologically-active compound which exists in public domain [3].…”